Dermatology
| Metastatic Melanoma
Dermatology
Metastatic Melanoma
Latent paraneoplastic dermatomyositis triggered by nivolumab treatment in a patient with metastatic melanoma. Case report and literature review
book_2
Source:
EADV Virtual - Poster session
calendar_today
Published on Medfyle:
November 2020
headphones
3
min
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- Checkpoint inhibitors have revolutionised the treatment of advanced and metastatic melanoma, but can lead to immune-related adverse events.
- This case looked at a patient with latent paraneoplastic dermatomyositis triggered by nivolumab treatment; diagnosis was confirmed with imaging and muscle biopsy.
- Comparison of serum samples from pre- and post nivolumab revealed pre-existing anti-TIF1γ antibodies, highlighting the need to perform an autoimmunity panel prior to treatment with a checkpoint inhibitor.
- Both muscular and skin improvement was achieved with pulsed methylprednisolone and six cycles of immunoglobulin.
Presenting Author
Read more
arrow_downward
Hide
arrow_upward
Laura Serra-Garcia, MD
Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain